Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Shares Outstanding (Weighted Average) (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $79.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 4.28% to $79.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $79.2 million, a 4.28% increase, with the full-year FY2025 number at $79.2 million, up 4.28% from a year prior.
  • Shares Outstanding (Weighted Average) was $79.2 million for Q4 2025 at Niagen Bioscience, roughly flat from $79.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $79.2 million in Q4 2025 to a low of $64.2 million in Q1 2021.
  • A 5-year average of $72.8 million and a median of $75.0 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): rose 10.02% in 2021, then grew 0.58% in 2024.
  • Niagen Bioscience's Shares Outstanding (Weighted Average) stood at $67.2 million in 2021, then increased by 3.79% to $69.7 million in 2022, then rose by 7.54% to $75.0 million in 2023, then rose by 1.26% to $75.9 million in 2024, then grew by 4.28% to $79.2 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Shares Outstanding (Weighted Average) are $79.2 million (Q4 2025), $79.0 million (Q3 2025), and $78.5 million (Q2 2025).